GLP-1 and Tirzepatide: What Makes This Medicine Different

Step 1: Understanding what GLP-1 receptor agonism actually does

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases in response to food. It tells the pancreas to produce insulin, signals to the brain that you have eaten, and slows the rate at which the stomach empties. Medicines that mimic GLP-1 exploit all three of those effects. Appetite drops. You feel full sooner and for longer. Blood-sugar spikes after meals are blunted.

Semaglutide, the active ingredient in Wegovy, works this way and is well-established. Tirzepatide does the same, but does not stop there. You can read more about the full receptor picture on how tirzepatide acts on both the GLP-1 and GIP pathways, but the short version is that layering in GIP activity appears to deepen the appetite-suppressing signal and improve how efficiently the body uses fat. The combined effect, in trial data, produces greater average weight loss than GLP-1 alone. For a closer look at how tirzepatide functions as a GLP and tirzepatide combination therapy, that page walks through the underlying mechanism in more detail.

The NHS medicines page for tirzepatide covers how it works in plain English and is worth reading alongside any clinical discussion you have.

Step 2: What the 'dual agonist' label means in real life

Calling tirzepatide a dual GIP and GLP-1 receptor agonist sounds technical. In practice it means a single weekly injection activates two separate receptor systems that both reduce hunger and regulate energy balance. Neither pathway is new; the combination is. No other weight-loss medicine licensed in the UK currently acts on both.

The clinical results reflect that. In SURMOUNT-1, published in the New England Journal of Medicine, adults without type 2 diabetes who took the 15 mg dose lost roughly 20–21% of their body weight on average over 72 weeks alongside a reduced-calorie diet and increased activity. The SURMOUNT-5 head-to-head trial then compared tirzepatide directly with semaglutide 2.4 mg and found greater average weight loss with tirzepatide, a result NICE referenced in its appraisal of the medicine (TA1026). Those figures come from controlled clinical conditions; individual outcomes vary. If you are interested in how the peptide science underpins those results, our page on GLP-1 peptide and tirzepatide explores that layer of the evidence.

Understanding the cost context matters too, tirzepatide is available privately at varying prices depending on dose and provider. The weight-loss treatment overview explains what to look for when comparing services.

Step 3: Who this treatment is licensed for, and who assesses it

The UK licence for tirzepatide in weight management covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. Lower thresholds can apply for some ethnic backgrounds under UK guidance. A BMI that appears to meet the criteria is not, on its own, enough, the prescriber looks at the full clinical picture, including other medicines, relevant history and any contraindications.

Treatment starts at the 2.5 mg dose, a level designed to let your body adjust before doses are titrated upward by your prescriber, typically in four-week steps. The available strengths run through 5, 7.5, 10, 12.5 and up to 15 mg. Telling the reader which strength they should be on is the prescriber's call, not something a general page can do, that conversation belongs in a consultation. Our page covering tirzepatide as a GLP-1 medicine gives useful context on how those dose steps relate to the drug's receptor activity.

If you want to understand tirzepatide in more depth before booking, the tirzepatide overview covers eligibility and the clinical trial programme in detail. Our clinical team brings the same rigour to every case reviewed through nume.

Step 4: What to expect from the consultation before treatment starts

Because tirzepatide is a prescription-only medicine, access in the UK requires a clinical assessment by a registered prescriber. At nume, a GPhC-registered Independent Prescriber reads every consultation personally, the same day, on working days. There is no algorithm making that decision.

The process includes photo-ID verification and a live weight check via video. If you are transferring from another service or requesting a dose increase, your prescriber will ask for evidence before the review proceeds. This is not bureaucracy for its own sake; it is the clinical standard that protects you. Most common side effects are gastrointestinal (nausea, loose stools, constipation) particularly after starting or moving to a higher dose. They usually ease within a week or two, and you can find further detail on the GLP-2 and tirzepatide page, which looks at how different receptor interactions can influence tolerability. The nume FAQs address common questions about how those first weeks tend to go.

We know that arriving at this page often means weeks of trying to get information you can trust. If you want to take the next step, speak to our prescribers via a free consultation, no commitment required, and a real clinician will review your answers the same day.